Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open?Label, Exploratory Trial
Mayo Clinic
Summary
The purpose of this study is to valuate the clinical efficacy of Bimzelx therapy in adults with Pityriasis Rubra Pilaris.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Clinical and/or histopathological diagnosis of PRP * Candidate for systemic therapy (PASI ≥ 10) * Body surface area of involvement ≥ 10% * Good general health as confirmed by medical history * Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and * Patients who read and sign an approved informed consent for this study Exclusion Criteria: * Vulnerable study population * Pregnant or nursing women * Women planning a pregnancy within the study period * Human immunodeficiency virus (HIV) positivity * Known history of adve…
Interventions
- DrugBimekizumab
Subjects will receive subcutaneous injection of 320 mg at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter for 24 weeks. For patients weighing ≥ 120 kg, 320 mg every 4 weeks after Week 16, for 24 weeks.
Location
- Mayo Clinic in FloridaJacksonville, Florida